Medicare Part D – Page 36 – medicarereport.org

Friday, September 11, 2026

Latest:

CMS Medicaid Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook August 1, 2023August 1, 2023 CMS, Dual-Eligible, medicare, Medicare Advantage, Medicare Part D, Mediciad

How Do Dual-Eligible Individuals Get Their Medicare Coverage?

(By Maria T. Peña, Maiss Mohamed, Jeannie Fuglesten Biniek, Juliette Cubanski, and Tricia Neuman for Kaiser Family Foundation Published: Jul

CMS Health Care Finance Health Care Redesign Medicare - General Part D/Prescription Drugs

Eileen Cook July 28, 2023July 28, 2023 Big Pharma, CMS, medicare, Medicare Drug Price Negotiation Program, Medicare Part D

What’s a fair price for a prescription drug? Medicare’s about to weigh in

(By Leslie Walker and Dan Gorenstein for NPR) Drugmakers around the globe are bracing for a major shakeup in how

CMS Health Care Finance Medicare - General Medicare Advantage Part D/Prescription Drugs

Eileen Cook July 27, 2023July 27, 2023 CMS, Healthcare Costs, Healthcare Finance, medicare, Medicare Advantage, Medicare Part D

Key Facts About Medicare Part D Enrollment and Costs in 2023

(By Juliette Cubanski and Anthony Damico for Kaiser Family Foundation Published: Jul 26, 2023) The Medicare Part D program provides

Aging CMS Legislative Update Medicare - General Part D/Prescription Drugs

Eileen Cook July 26, 2023July 26, 2023 CMS, medicare, Medicare Part D, Older Adults, Ozempic, Treat and Reduce Obesity Act

New Weight Loss Drugs Carry High Price Tags and Lots of Questions for Seniors

(By Judith Graham for KFF Health News) Corlee Morris has dieted throughout her adult life. After her weight began climbing

Alzheimer’s/Dementia FDA Part D/Prescription Drugs

Eileen Cook July 18, 2023July 18, 2023 Alzheimer’s Disease, Donanemab, FDA, Medicare Part D, Older Adults

An experimental Alzheimer’s drug outperforms one just approved by the FDA

(By Jon Hamilton for NPR) Patients in the early stages of Alzheimer’s may soon have a new option to stave

Alzheimer’s/Dementia CMS FDA Health Care Finance Medicare - General Part D/Prescription Drugs

Eileen Cook July 14, 2023July 14, 2023 Alzheimer’s Disease, CMS, Leqembi, medicare, Medicare Advantage, Medicare Part D, Older Adults

Will the new Alzheimer’s drug put pressure on Medicare premiums?

The FDA approved the drug Leqembi, and Medicare will cover the new expensive new drug that promises the slowing the

CMS Health Care Finance Part D/Prescription Drugs

Eileen Cook July 13, 2023July 13, 2023 CMS, medicare, Medicare Part D, Prescription drug coverage, Prescription Drug Spending

10 Prescription Drugs Accounted for $48 Billion in Medicare Part D Spending in 2021, or More Than One-Fifth of Part D Spending That Year

(By Chris Lee for The Kaiser Family Foundation published July 12, 2023) A new KFF analysis finds that the 10

CMS Health Care Finance Health Insurance HHS Medical Debt Part D/Prescription Drugs

Eileen Cook July 11, 2023July 11, 2023 Junk Health Plans, Medical debt, medicare, Medicare Drug Price Negotiation Program, Medicare Part D, Surprise health care bills

HHS Announces Actions to Protect Consumers and Lower Health Care Costs

(Source - www.cms.gov/newsroom) The U.S. Department of Health and Human Services (HHS), announced actions to protect consumers from junk health

Aging Alzheimer’s/Dementia CMS FDA Health Care Finance Part D/Prescription Drugs

Eileen Cook July 11, 2023July 11, 2023 Alzheimer’s Disease, CMS, Healthcare Costs, Lecanemab Drug, medicare, Medicare Part D, Older Adults

Leqembi could cost Medicare up to $17.8B

(By Rylee Wilson for Becker’s Hospital Review ) Leqembi, the newly-approved drug that can slow the progression of Alzhemier’s disease,

Alzheimer’s/Dementia CMS FDA Part D/Prescription Drugs

Eileen Cook July 10, 2023July 10, 2023 Alzheimer’s Disease, CMS, FDA, Lecanemab Drug, Medicare Part D

Statement: Broader Medicare Coverage of Leqembi Available Following FDA Traditional Approval

(Source - www.cms.gov/newsroom) Broader Medicare coverage is now available for Biogen and Eisai’s Leqembi (the brand name for lecanemab) following